Everolimus

(Afinitor®)

Everolimus

Drug updated on 11/13/2023

Dosage FormTablet (oral: afinitor;.5 mg, 5 mg, 7.5 mg, and 10 mg) Tablet (oral: afinitor disperz; 2 mg, 3 mg, and 5 mg)
Drug ClassKinase inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Afinitor:
  • For the treatment of postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
  • For the treatment of adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.
  • For the treatment of adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
  • For the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
  • Afinitor and Afinitor Disperz:
  • For the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
  • Afinitor Disperz:
  • For the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSCassociated partial-onset seizures.

Product Monograph / Prescribing Information

Document TitleYearSource
Afinitor (everolimus) Prescribing Information.2022Novartis Pharmaceuticals Corporation East Hanover, New Jersey

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
SEOM clinical guideline for treatment of kidney cancer (2019).2020Clinical and Translational Oncology